Table 3

Correlation between NY-ESO-1 and LAGE-1 mRNA expression and clinicopathological features in EOC

Pathological and clinical featuresNY-ESO-1 positiveLAGE-1 positive
All tumorsa (n = 107)32 (30%)22 (21%)
Age [median (range)], years61.0 (22–84)63.0 (42–89)
Follow-up [median (range)], months29.2 (2.1–109)22.7 (1–83)
Tumor grade (n)
 G1
 G242
 G32820
FIGO stage (n)
 Ia2
 Ib
 Ic1
 IIb1
 IIC1
 IIIa1
 IIIb1
 IIIc2712
 IV35
Histology (n)
 Papillary serous2414
 Clear cell13
 Endometroid
 Mucinous21
 Undifferentiated1
 Others53
Clinical response (n)
 Complete response148
 Partial response1611
 Progression1
 Unknown22
Total recurrences/persistent disease (n)2416
Dead of diseaseb (n)129
Alive with disease (n)138
Alive with no evidence of disease (n)75
  • a The expression of either NY-ESO-1 or LAGE-1 mRNA was found in 42/107 (40%) of EOC specimens.

  • b Median survival for patients with NY-ESO-1 mRNA-positive and -negative tumors was 50 (CI, 19–81) and 57 (CI, 43–71) months, respectively (P = 0.72). Median survival for patients with LAGE-1 mRNA-positive and -negative tumors could not be determined (P = 0.22).